期刊文献+

CIP耐药的铜绿假单胞菌两种分子耐药机制关系的研究 被引量:5

Study on the relationship of gyrA and parC gene mutation and pump efflux in Pseudomonas aeruginosa clinical isolates of ciprofloxacin resistance
下载PDF
导出
摘要 目的探讨环丙沙星(CIP)耐药的铜绿假单胞菌临床分离株主动外排药物与gyrA、parC基因突变的关系。方法联合碳酰氰基-对-氯苯腙(CCCP)和CIP对CIP耐药的铜绿假单胞菌株进行主动外排阳性株和阴性株的筛选,并对这些菌株的gyrA、parC基因进行聚合酶链式反应-限制性片段长度多态性分析(PCR-RFLP)。结果57%(55/97)的CIP耐药菌株最小抑菌浓度(MIC)可被逆转,gyrA单基因突变率为65%,gyrA和parC双基因突变率为35%,未发现parC单基因突变的菌株。主动外排阳性组与阴性组gyrA、parC基因突变情况差异无显著性。结论在本地区铜绿假单胞菌对CIP的耐药机制中,主动外排系统表达上调与抗菌药物作用靶位的改变均占有重要的地位,两者可能是并存的两种相对独立的机制。 Objective To study the relationship ofgyrA andparC gene mutation and pump effiux in Pseudomonas aeruginosa clinical isolates of ciprofloxacin resistance. Methods The dilution method was used to determine minimum inhibitory concentration(MIC) with or without the effiux pump inhibitor Carbonyl Cyarude-3-chlorophcnylhydrazone(CCCP). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect the mutation of gyrA and parC. Results. The MIC of 57% (55/97) ciprofloxacin-resistant strains could be significantly reduced by CCCP. The rate of gyrA single gene mutation was 65% ,while the rate of gyrA and parC double gene mutation was 35%. No single gene mutation of parC could be found in the test. There was no statistics difference in gyrA or parC gene mutation between the strains with or without effiux pump. Conclusion In ciprofloxacin resistance mechanism of P. aeruginosa clinical isolates, both gyrA and parC gene mutation and pump effiux play very important roles ,but might function independently.
出处 《中国微生态学杂志》 CAS CSCD 2008年第2期131-134,共4页 Chinese Journal of Microecology
基金 广州市教育局立项资助(项目编号:1044)
关键词 环丙沙星耐药 铜绿假单胞菌 主动外排 基因突变 Ciprofloxacin resistance Pseudomonas aeruginosa Efflux pump Gene mutation
  • 相关文献

参考文献7

  • 1MAC GOWAN A P, BOWKER K E. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model [ J ]. Anti microb Agents Chemother,2003,47 ( 3 ) : 1096.
  • 2赵廷坤,凌保东,周歧新.铜绿假单胞菌主动外排系统研究进展[J].四川生理科学杂志,2004,26(3):126-130. 被引量:7
  • 3HIGGINS P G,FLUIT A C,MILATOBIC D,et al. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa [ J]. Int J Antimicrob Agents,2003,21 (5) :409-413.
  • 4HIDEAKI MASEDA, HIROSHI YONEYAMA,TAI JI NAKAE. Assignment of the substrate-selective subunits of the MexEF-OprN multidrug eftlux pump of Pseudomonas aeruglnosa [ J ]. Antimicrob Agents Chemother ,2000,44:658.
  • 5AKASAKA T, TANAKA M, YAMAGUCHI A, et al. Type Ⅱ topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999:role of target enzyme in mechanism of fluoroquinolone resistance [ J ]. Antimicrob Agents Chemother,2001,45 ( 8 ) :2263.
  • 6LI X Z,POOLE K,MKAIDO H. Contributions of Mex AB-OprM and an EmrE homolog to intrinsic resistance of Pseudomonas aeruglnosa to aminoglycosides dyes[ J]. Antimicrob Agents Chemother,2003 ,47 :27-33.
  • 7穆雪鹍,陈升汶,王沙燕.铜绿假单胞菌对氟喹诺酮类药物耐药机制的研究进展[J].中华医院感染学杂志,2004,14(11):1316-1319. 被引量:17

二级参考文献53

  • 1[1]Bonfiglio G, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey[J]. Antimicrob Chemother, 1998, 41(2): 307-310.
  • 2[2]Segatore B, Setacci D, Perilli M, et al. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1999, 43(2): 428-431.
  • 3[3]Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different[J]. Diagn Microbiol Infect Dis, 2001, 41(3): 161-163.
  • 4[4]Kirby JT, Mutnick AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)[J]. Diagn Microbiol Infect Dis, 2002, 43(4): 303-309.
  • 5[5]Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST (tracking resistance in the United States today) and TSN (the surveillance network) data for the United States[J]. Int J Antimicrob Agents, 2002, 19(1): 21-31.
  • 6[6]Sheng WH, Chen YC, Wang JT, et al. Emerging fluoro-quinolone-resistance for common clinically important Gram-negative bacteria in Taiwan[J]. Diagn Microbiol Infect Dis, 2002, 43(2): 141-147.
  • 7[7]Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals[J]. Am J Health-System Pharm, 2003, 60(19): 1962-1970.
  • 8[8]Kukeishi A, Diver JM, Beckthold B, et al. Cloning and nucleotide sequence of P. aeruginosa gyr A gene from PA01 and quinolone-resistant clinical isolates[J]. Antimicrob Agents Chemother, 1994, 38(9): 1944-1952.
  • 9[9]Yonezawa M, Takahata M, Matsubara N, et al. DNA gyrase gyr A mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1995, 39(9): 1970-1972.
  • 10[10]Takenouchi T, Sahagawa E, Sugawara M. Detection of gyrA mutation among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones[J]. Antimicrob Agents Chemother, 1999, 43(2): 406-409.

共引文献22

同被引文献45

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部